Abstract
Background Studies have identified individual blood biomarkers associated with chronic obstructive pulmonary disease (COPD) and related phenotypes. However, complex diseases such as COPD typically involve changes in multiple molecules with interconnections that may not be captured when considering single molecular features.
Methods Leveraging proteomic data from 3,173 COPDGene Non-Hispanic White (NHW) and African American (AA) participants, we applied sparse multiple canonical correlation network analysis (SmCCNet) to 4,776 proteins assayed on the SomaScan v4.0 platform to derive sparse networks of proteins associated with current vs. former smoking status, airflow obstruction, and emphysema quantitated from high-resolution computed tomography scans. We then used NetSHy, a dimension reduction technique leveraging network topology, to produce summary scores of each proteomic network, referred to as NetSHy scores. We next performed genome-wide association study (GWAS) to identify variants associated with the NetSHy scores, or network quantitative trait loci (nQTLs). Finally, we evaluated the replicability of the networks in an independent cohort, SPIROMICS.
Results We identified networks of 13 to 104 proteins for each phenotype and exposure in NHW and AA, and the derived NetSHy scores significantly associated with the variable of interests. Networks included known (sRAGE, ALPP, MIP1) and novel molecules (CA10, CPB1, HIS3, PXDN) and interactions involved in COPD pathogenesis. We observed 7 nQTL loci associated with NetSHy scores, 4 of which remained after conditional analysis. Networks for smoking status and emphysema, but not airflow obstruction, demonstrated a high degree of replicability across race groups and cohorts.
Conclusions In this work, we apply state-of-the-art molecular network generation and summarization approaches to proteomic data from COPDGene participants to uncover protein networks associated with COPD phenotypes. We further identify genetic associations with networks. This work discovers protein networks containing known and novel proteins and protein interactions associated with clinically relevant COPD phenotypes across race groups and cohorts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NHLBI R01 HL152735, U01 HL089897 and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. COPDGene proteomics profiling was funded by through R01 HL137995 (Bowler, Kechris). SPIROMICS proteomic sample profiling was funded by Novartis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NIH-sponsored multicenter Genetic Epidemiology of COPD (COPDGene) study was approved and reviewed by the institutional review board (ClinicalTrials.gov Identifier: NCT00608764) including: National Jewish IRB, Partners Human Research Committee, Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals, Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals, Columbia University Medical Center IRB, The Duke University Health System Institutional Review Board for Clinical Investigations (DUHS IRB), Johns Hopkins Medicine Institutional Review Boards (JHM IRB), The John F. Wolf, MD Human Subjects Committee of Harbor UCLA Medical Center, Morehouse School of Medicine Institutional Review Board, Temple University Office for Human Subjects Protections Institutional Review Board, The University of Alabama at Birmingham Institutional Review Board for Human Use, University of California, San Diego Human Research Protections Program, The University of Iowa Human Subjects Office, VA Ann Arbor Healthcare System IRB, University of Minnesota Research Subjects Protection Programs (RSPP), University of Pittsburgh Institutional Review Board, UT Health Science Center San Antonio Institutional Review Board, Health Partners Research Foundation Institutional Review Board, Medical School Institutional Review Board (IRBMED), Minneapolis VAMC IRB Institutional Review Board/Research Review Committee Saint Vincent Hospital Fallon Clinic Fallon Community Health Plan. All study participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The SomaScan data supporting the conclusions of this article are available from the data coordinating centers of COPDGene and SPIROMICS respectively. The genomic data is available through TOPMed.
